ANTH
Anthera Pharmaceuticals, Inc.
ANTH
ANTH
Delisted
ANTH was delisted on the 27th of June, 2018.
35 hedge funds and large institutions have $3.21M invested in Anthera Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
9
Closed
11
Calls
$427K
Puts
–
Net Calls
+$427K
Net Calls Change
-$158K
Top Buyers
1 |
TSS
Two Sigma Securities
New York
|
+$71K |
2 |
Neuberger Berman Group
New York
|
+$49K |
3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$45.7K |
4 |
UBS Group
Zurich,
Switzerland
|
+$32.8K |
5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27K |
Top Sellers
1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$779K |
2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$83.6K |
3 |
ECM
Element Capital Management
New York
|
-$70K |
4 |
Goldman Sachs
New York
|
-$69K |
5 |
Northern Trust
Chicago,
Illinois
|
-$60.8K |